Loading...

David Cheresh

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentPathology
Address9500 Gilman Drive #0695
La Jolla CA 92093
Phone858-822-2232
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Targeting a non-canonical RAS-driven pathway in pancreatic cancer
    NIH/NCI R01CA168692Jul 1, 2012 - Apr 30, 2017
    Role: Principal Investigator
    MicroRNA regulation of RasGAP's during angiogenesis
    NIH/NHLBI R01HL103956Jun 15, 2011 - May 31, 2016
    Role: Principal Investigator
    Identification of novel pancreatic cancer biomarkers
    NIH/NCI R21CA129660Sep 1, 2007 - Aug 31, 2009
    Role: Principal Investigator
    Endothelial Barrier Function Regulation by VEGF
    NIH/NHLBI R01HL078912Aug 1, 2005 - Jul 31, 2010
    Role: Principal Investigator
    Targeting Vessels in Tumors
    NIH P01CA104898May 16, 2005 - Aug 31, 2011
    Role: Co-Investigator
    Biological Response to the Extracellular Matrix
    NIH/NCI R13CA094245Apr 1, 2002 - Dec 31, 2002
    Role: Principal Investigator
    Regulation of cell invasion by apoptotic mechanisms
    NIH/NCI R01CA095262Mar 1, 2002 - May 31, 2012
    Role: Principal Investigator
    Angiogenesis and Mircrocirculation Conference
    NIH/NCI R13CA092869Jun 1, 2001 - May 31, 2002
    Role: Principal Investigator
    VASCULAR CELL BIOLOGY CONFERENCE
    NIH/NHLBI R13HL065737Aug 1, 2000 - Jul 31, 2001
    Role: Principal Investigator
    Combinatorial Chemistry and Cancer Target
    NIH P01CA078045May 7, 1998 - Feb 28, 2010
    Role: Co-Investigator
    Integrin Signaling in Hemostasis and Blood Diseases
    NIH/NHLBI P01HL057900Apr 1, 1997 - Jan 31, 2014
    Role: Co-Investigator
    VASCULAR INTEGRIN IN ANGIOGENESIS OF BREAST CANCER
    NIH/NHLBI R01HL054444Jun 1, 1995 - May 31, 1999
    Role: Principal Investigator
    CRAF-mediated vascular resistance to cancer therapies
    NIH/NCI R01CA050286Aug 1, 1989 - Feb 29, 2020
    Role: Principal Investigator
    VEGF and PDGF in angiogenesis and tumor progression
    NIH/NCI R37CA050286Aug 1, 1989 - Apr 30, 2014
    Role: Principal Investigator
    Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors
    NIH/NCI R01CA045726Apr 1, 1988 - Jan 31, 2018
    Role: Principal Investigator
    PROPERTIES OF MELANOMA CELL SURFACE GLYCOLIPIDS
    NIH/NCI F32CA007544Mar 1, 1985
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang H, Lapek J, Fujimura K, Strnadel J, Liu B, Gonzalez DJ, Zhang W, Watson F, Yu V, Liu C, Melo CM, Miller YI, Elliott KC, Cheresh DA, Klemke RL. Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription. Cell Discov. 2018; 4:26. PMID: 29872538.
      View in: PubMed
    2. Cosset É, Weis SM, Cheresh DA. Re-thinking the preclinical development of GBM therapeutics. Oncoscience. 2018 Jan; 5(1-2):11-12. PMID: 29556513.
      View in: PubMed
    3. Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier JS. Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. J Clin Invest. 2018 Jan 02; 128(1):531-544. PMID: 29227280.
      View in: PubMed
    4. Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 2017 Dec 11; 32(6):856-868.e5. PMID: 29198914.
      View in: PubMed
    5. Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh DA. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017 12; 7(12):1464-1479. PMID: 28893801.
      View in: PubMed
    6. Hazell AS, Afadlal S, Cheresh DA, Azar A. Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy. Neurosci Lett. 2017 Mar 06; 642:163-167. PMID: 28109775.
      View in: PubMed
    7. Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani SJ, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh DA, Anand S. MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun. 2016 Nov 25; 7:13597. PMID: 27886180.
      View in: PubMed
    8. Advani SJ, Camargo MF, Seguin L, Mielgo A, Anand S, Hicks AM, Aguilera J, Franovic A, Weis SM, Cheresh DA. Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nat Commun. 2015 Sep 03; 6:8154. PMID: 26333361; PMCID: PMC4559870.
    9. Franovic A, Elliott KC, Seguin L, Camargo MF, Weis SM, Cheresh DA. Glioblastomas require integrin avß3/PAK4 signaling to escape senescence. Cancer Res. 2015 Nov 01; 75(21):4466-73. PMID: 26297735; PMCID: PMC4631634 [Available on 11/01/16].
    10. Acevedo LM, Lindquist JN, Walsh BM, Sia P, Cimadamore F, Chen C, Denzel M, Pernia CD, Ranscht B, Terskikh A, Snyder EY, Cheresh DA. hESC Differentiation toward an Autonomic Neuronal Cell Fate Depends on Distinct Cues from the Co-Patterning Vasculature. Stem Cell Reports. 2015 Jun 09; 4(6):1075-88. PMID: 26004631; PMCID: PMC4471822.
    11. Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015 Apr; 25(4):234-40. PMID: 25572304; PMCID: PMC4380531.
    12. Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A, Yebra M, Shattil SJ, Cheresh DA. Integrin avß3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell. 2014 Aug 11; 30(3):295-308. PMID: 25117682; PMCID: PMC4147869.
    13. Seguin L, Gozo M, Weis SM, Cheresh DA. Targeting the Achilles' heel of drug-resistant cancer stem cells. Cell Cycle. 2014; 13(13):2017-8. PMID: 24906000; PMCID: PMC4111689.
    14. Seguin L, Weis SM, Cheresh DA. Variety in the tumor microenvironment: integrin splicing regulates stemness. Cell Stem Cell. 2014 May 01; 14(5):557-8. PMID: 24792112.
      View in: PubMed
    15. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin ß3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. PMID: 24747441.
      View in: PubMed
    16. Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, Ward KK, Walsh CT, Miller NL, Ghassemian M, Turowski P, Dejana E, Weis S, Cheresh DA, Schlaepfer DD. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol. 2014 Jan 20; 204(2):247-63. PMID: 24446483; PMCID: PMC3897185.
    17. Cheresh DA, Stupack DG. Tumor angiogenesis: putting a value on plastic GEMMs. Circ Res. 2014 Jan 03; 114(1):9-11. PMID: 24385501; PMCID: PMC4090242.
    18. Westenskow PD, Kurihara T, Aguilar E, Scheppke EL, Moreno SK, Wittgrove C, Marchetti V, Michael IP, Anand S, Nagy A, Cheresh D, Friedlander M. Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. J Clin Invest. 2013 Nov; 123(11):4900-8. PMID: 24084735; PMCID: PMC3809796.
    19. Han J, Zhang G, Welch EJ, Liang Y, Fu J, Vogel SM, Lowell CA, Du X, Cheresh DA, Malik AB, Li Z. A critical role for Lyn kinase in strengthening endothelial integrity and barrier function. Blood. 2013 Dec 12; 122(25):4140-9. PMID: 24108461; PMCID: PMC3862279.
    20. Weis SM, Cheresh DA. A wake-up call for hibernating tumour cells. Nat Cell Biol. 2013 Jul; 15(7):721-3. PMID: 23817234.
      View in: PubMed
    21. Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, Wang HY, Cheresh DA, Varner J. PI3Ka activates integrin a4ß1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A. 2013 May 28; 110(22):9042-7. PMID: 23671068.
      View in: PubMed
    22. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012 Jul 10; 22(1):21-35. PMID: 22789536; PMCID: PMC4068350.
    23. Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, Uryu S, Weis SM, Cheresh DA, Schlaepfer DD. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol. 2012 Jun 25; 197(7):907-19. PMID: 22734001; PMCID: PMC3384409.
    24. Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA. EGFR-mediated carcinoma cell metastasis mediated by integrin avß5 depends on activation of c-Src and cleavage of MUC1. PLoS One. 2012; 7(5):e36753. PMID: 22586492; PMCID: PMC3346745.
    25. Yu PT, Babicky M, Jaquish D, French R, Marayuma K, Mose E, Niessen S, Hoover H, Shields D, Cheresh D, Cravatt BF, Lowy AM. The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. Int J Cancer. 2012 Oct 15; 131(8):1744-54. PMID: 22275185; PMCID: PMC3424378.
    26. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012 Jan 17; 22(1):146-57. PMID: 22264731; PMCID: PMC3266538.
    27. Anand S, Cheresh DA. Emerging Role of Micro-RNAs in the Regulation of Angiogenesis. Genes Cancer. 2011 Dec; 2(12):1134-8. PMID: 22866204; PMCID: PMC3411126.
    28. Scheppke L, Murphy EA, Zarpellon A, Hofmann JJ, Merkulova A, Shields DJ, Weis SM, Byzova TV, Ruggeri ZM, Iruela-Arispe ML, Cheresh DA. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood. 2012 Mar 01; 119(9):2149-58. PMID: 22134168; PMCID: PMC3311249.
    29. Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011 Dec; 2(12):1159-65. PMID: 22866207; PMCID: PMC3411133.
    30. Cheresh DA. Monographs editor. Genes Cancer. 2011 Dec; 2(12):1071. PMID: 22866197; PMCID: PMC3411130.
    31. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA. A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med. 2011 Nov 13; 17(12):1641-5. PMID: 22081024; PMCID: PMC3233644.
    32. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011 Nov 07; 17(11):1359-70. PMID: 22064426.
      View in: PubMed
    33. Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA. EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene. 2012 May 31; 31(22):2783-93. PMID: 21963850; PMCID: PMC3711644.
    34. Weis SM, Cheresh DA. aV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a006478. PMID: 22229119; PMCID: PMC3234453.
    35. Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY, Ohh M. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med. 2011 Jun 19; 17(7):845-53. PMID: 21685897; PMCID: PMC3221316.
    36. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k?, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011 Jun 14; 19(6):715-27. PMID: 21665146; PMCID: PMC3144144.
    37. Aspinall RJ, Weis SM, Barnes L, Lutu-Fuga K, Bylund DJ, Pockros PJ, Cheresh DA. A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels. Liver Int. 2011 Sep; 31(8):1222-30. PMID: 21745297; PMCID: PMC3337519.
    38. Anand S, Cheresh DA. MicroRNA-mediated regulation of the angiogenic switch. Curr Opin Hematol. 2011 May; 18(3):171-6. PMID: 21423013; PMCID: PMC3159578.
    39. Murphy EA, Majeti BK, Mukthavaram R, Acevedo LM, Barnes LA, Cheresh DA. Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther. 2011 Jun; 10(6):972-82. PMID: 21518727; PMCID: PMC3112300.
    40. Shields DJ, Murphy EA, Desgrosellier JS, Mielgo A, Lau SK, Barnes LA, Lesperance J, Huang M, Schmedt C, Tarin D, Lowy AM, Cheresh DA. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene. 2011 May 05; 30(18):2123-34. PMID: 21242978; PMCID: PMC3104672.
    41. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010 Aug; 16(8):909-14. PMID: 20676106; PMCID: PMC3094020.
    42. Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, Feral C, Papayannopoulou T, Lowy A, Blair SL, Cheresh D, Ginsberg M, Varner JA. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010 Apr 15; 70(8):3042-51. PMID: 20388801; PMCID: PMC2856096.
    43. Lindquist JN, Cheresh DA, Snyder EY. Derivation of vasculature from embryonic stem cells. Curr Protoc Stem Cell Biol. 2010 Mar; Chapter 1:Unit 1F.9. PMID: 20200855.
      View in: PubMed
    44. Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh DA. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4299-304. PMID: 20154271; PMCID: PMC2840076.
    45. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010 Jan; 10(1):9-22. PMID: 20029421; PMCID: PMC4383089.
    46. Shields DJ, Niessen S, Murphy EA, Mielgo A, Desgrosellier JS, Lau SK, Barnes LA, Lesperance J, Bouvet M, Tarin D, Cravatt BF, Cheresh DA. RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2189-94. PMID: 20080647; PMCID: PMC2836678.
    47. Greenberg JI, Cheresh DA. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther. 2009 Nov; 9(11):1347-56. PMID: 19761418.
      View in: PubMed
    48. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ, Cheresh DA. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009 Oct; 15(10):1163-9. PMID: 19734908; PMCID: PMC2759406.
    49. Koh W, Sachidanandam K, Stratman AN, Sacharidou A, Mayo AM, Murphy EA, Cheresh DA, Davis GE. Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. J Cell Sci. 2009 Jun 01; 122(Pt 11):1812-22. PMID: 19435802; PMCID: PMC2684834.
    50. Weis SM, Stupack DG, Cheresh DA. Agonizing integrin antagonists? Cancer Cell. 2009 May 05; 15(5):359-61. PMID: 19411065.
      View in: PubMed
    51. Makale M, McElroy M, O'Brien P, Hoffman RM, Guo S, Bouvet M, Barnes L, Ingulli E, Cheresh D. Extended-working-distance multiphoton micromanipulation microscope for deep-penetration imaging in live mice and tissue. J Biomed Opt. 2009 Mar-Apr; 14(2):024032. PMID: 19405761; PMCID: PMC3098575.
    52. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK, Cheresh DA. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 2009 Feb 15; 69(4):1383-91. PMID: 19208836; PMCID: PMC2741736.
    53. Acevedo LM, Cheresh DA. Suppressing NFAT increases VEGF signaling in hemangiomas. Cancer Cell. 2008 Dec 09; 14(6):429-30. PMID: 19061833.
      View in: PubMed
    54. Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar; 328(3):758-65. PMID: 19056934.
      View in: PubMed
    55. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008 Dec 11; 456(7223):809-13. PMID: 18997771; PMCID: PMC2605188.
    56. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008 Dec 11; 456(7223):814-8. PMID: 18997773; PMCID: PMC3103772.
    57. Cheresh DA, Stupack DG. Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene. 2008 Oct 20; 27(48):6285-98. PMID: 18931694.
      View in: PubMed
    58. Rupp PA, Visconti RP, Czirók A, Cheresh DA, Little CD. Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. Mol Biol Cell. 2008 Dec; 19(12):5529-40. PMID: 18923152; PMCID: PMC2592652.
    59. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9343-8. PMID: 18607000; PMCID: PMC2453735.
    60. Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J, Doukas J, Cao J, Noronha G, Yee S, Weis S, Martin MB, Soll R, Cheresh DA, Friedlander M. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest. 2008 Jun; 118(6):2337-46. PMID: 18483622; PMCID: PMC2381746.
    61. Serban D, Leng J, Cheresh D. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res. 2008 Jun 06; 102(11):1350-8. PMID: 18467631; PMCID: PMC2743877.
    62. Weis SM, Lim ST, Lutu-Fuga KM, Barnes LA, Chen XL, Göthert JR, Shen TL, Guan JL, Schlaepfer DD, Cheresh DA. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 2008 Apr 07; 181(1):43-50. PMID: 18391070; PMCID: PMC2287283.
    63. Acevedo LM, Weis SM, Cheresh DA. Robo4 counteracts VEGF signaling. Nat Med. 2008 Apr; 14(4):372-3. PMID: 18391935.
      View in: PubMed
    64. Acevedo LM, Barillas S, Weis SM, Göthert JR, Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 2008 Mar 01; 111(5):2674-80. PMID: 18180379; PMCID: PMC2254547.
    65. Cheresh DA. Preface: a tribute to Dr. Judah Folkman. Methods Enzymol. 2008; 443:xv-xvi. PMID: 18772007.
      View in: PubMed
    66. Yang XL, Kapoor M, Otero FJ, Slike BM, Tsuruta H, Frausto R, Bates A, Ewalt KL, Cheresh DA, Schimmel P. Gain-of-function mutational activation of human tRNA synthetase procytokine. Chem Biol. 2007 Dec; 14(12):1323-33. PMID: 18096501; PMCID: PMC2693404.
    67. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007 Apr 05; 446(7136):690-4. PMID: 17377533.
      View in: PubMed
    68. Alavi AS, Acevedo L, Min W, Cheresh DA. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res. 2007 Mar 15; 67(6):2766-72. PMID: 17363598.
      View in: PubMed
    69. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19866-71. PMID: 17172449; PMCID: PMC1702529.
    70. Weis SM, Lindquist JN, Barnes LA, Lutu-Fuga KM, Cui J, Wood MR, Cheresh DA. Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood. 2007 Mar 01; 109(5):1962-70. PMID: 17062734; PMCID: PMC1801042.
    71. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, Cheresh DA, Schlaepfer DD. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene. 2006 Sep 28; 25(44):5969-84. PMID: 16682956.
      View in: PubMed
    72. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature. 2006 Jan 05; 439(7072):95-9. PMID: 16397500.
      View in: PubMed
    73. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005 Sep 22; 437(7058):497-504. PMID: 16177780.
      View in: PubMed
    74. Potter MD, Barbero S, Cheresh DA. Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem. 2005 Sep 09; 280(36):31906-12. PMID: 16027153.
      View in: PubMed
    75. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004 Oct 25; 167(2):223-9. PMID: 15504909; PMCID: PMC2172541.
    76. Stupack DG, Cheresh DA. A Bit-role for integrins in apoptosis. Nat Cell Biol. 2004 May; 6(5):388-9. PMID: 15122265.
      View in: PubMed
    77. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest. 2004 Mar; 113(6):885-94. PMID: 15067321; PMCID: PMC362122.
    78. McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. J Immunother. 2004 Mar-Apr; 27(2):161-75. PMID: 14770088.
      View in: PubMed
    79. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol. 2004; 64:207-38. PMID: 15563949.
      View in: PubMed
    80. Stupack DG, Cheresh DA. Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene. 2003 Dec 08; 22(56):9022-9. PMID: 14663480.
      View in: PubMed
    81. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol. 2003 Sep 01; 162(5):933-43. PMID: 12952943; PMCID: PMC2172815.
    82. Hood JD, Cheresh DA. Building a better Trap. Proc Natl Acad Sci U S A. 2003 Jul 22; 100(15):8624-5. PMID: 12861079; PMCID: PMC166360.
    83. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003 Jul 04; 301(5629):94-6. PMID: 12843393.
      View in: PubMed
    84. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KS, Cheresh DA, Schlaepfer DD. Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003 Mar 03; 160(5):753-67. PMID: 12615911; PMCID: PMC2173366.
    85. Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J. 2002 Dec 02; 21(23):6289-302. PMID: 12456636; PMCID: PMC136935.
    86. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci. 2002 Oct 01; 115(Pt 19):3729-38. PMID: 12235283.
      View in: PubMed
    87. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002 Jun 28; 296(5577):2404-7. PMID: 12089446.
      View in: PubMed
    88. Wakasugi K, Slike BM, Hood J, Ewalt KL, Cheresh DA, Schimmel P. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem. 2002 Jun 07; 277(23):20124-6. PMID: 11956181.
      View in: PubMed
    89. Kiosses WB, Hood J, Yang S, Gerritsen ME, Cheresh DA, Alderson N, Schwartz MA. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res. 2002 Apr 05; 90(6):697-702. PMID: 11934838.
      View in: PubMed
    90. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol. 2002 Apr 01; 157(1):149-60. PMID: 11927607; PMCID: PMC2173263.
    91. Nemerow GR, Cheresh DA. Herpesvirus hijacks an integrin. Nat Cell Biol. 2002 Apr; 4(4):E69-71. PMID: 11944033.
      View in: PubMed
    92. Cheresh DA, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med. 2002 Mar; 8(3):193-4. PMID: 11875466.
      View in: PubMed
    93. Strömblad S, Fotedar A, Brickner H, Theesfeld C, Aguilar de Diaz E, Friedlander M, Cheresh DA. Loss of p53 compensates for alpha v-integrin function in retinal neovascularization. J Biol Chem. 2002 Apr 19; 277(16):13371-4. PMID: 11856728.
      View in: PubMed
    94. Stupack DG, Cheresh DA. ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci STKE. 2002 Feb 12; 2002(119):pe7. PMID: 11842241.
      View in: PubMed
    95. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002 Feb; 2(2):91-100. PMID: 12635172.
      View in: PubMed
    96. Otani A, Slike BM, Dorrell MI, Hood J, Kinder K, Ewalt KL, Cheresh D, Schimmel P, Friedlander M. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):178-83. PMID: 11773625; PMCID: PMC117535.
    97. Wakasugi K, Slike BM, Hood J, Otani A, Ewalt KL, Friedlander M, Cheresh DA, Schimmel P. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):173-7. PMID: 11773626; PMCID: PMC117534.
    98. Kessler TA, Pfeifer A, Silletti S, Mesters RM, Berdel WE, Verma I, Cheresh D. Matrix metalloproteinase/integrin interactions as target for anti-angiogenic treatment strategies. Ann Hematol. 2002; 81 Suppl 2:S69-70. PMID: 12611083.
      View in: PubMed
    99. Hood JD, Cheresh DA. Targeted delivery of mutant Raf kinase to neovessels causes tumor regression. Cold Spring Harb Symp Quant Biol. 2002; 67:285-91. PMID: 12858551.
      View in: PubMed
    100. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001 Oct 29; 155(3):459-70. PMID: 11684710; PMCID: PMC2150834.
    101. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol. 2001 Oct; 13(5):563-8. PMID: 11544024.
      View in: PubMed
    102. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PM. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery. 2001 Aug; 49(2):380-9; discussion 390. PMID: 11504114.
      View in: PubMed
    103. Li E, Brown SL, Stupack DG, Puente XS, Cheresh DA, Nemerow GR. Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol. 2001 Jun; 75(11):5405-9. PMID: 11333925; PMCID: PMC114949.
    104. Pfeifer A, Kessler T, Yang M, Baranov E, Kootstra N, Cheresh DA, Hoffman RM, Verma IM. Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol Ther. 2001 Mar; 3(3):319-22. PMID: 11273773.
      View in: PubMed
    105. Boger DL, Goldberg J, Silletti S, Kessler T, Cheresh DA. Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). J Am Chem Soc. 2001 Feb 21; 123(7):1280-8. PMID: 11456699.
      View in: PubMed
    106. Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL, Chopp M, Cheresh DA. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med. 2001 Feb; 7(2):222-7. PMID: 11175854.
      View in: PubMed
    107. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A. 2001 Jan 02; 98(1):119-24. PMID: 11134507; PMCID: PMC14554.
    108. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001 Jan; 48(1):151-7. PMID: 11152340.
      View in: PubMed
    109. Bello L, Zhang J, Nikas DC, Strasser JF, Villani RM, Cheresh DA, Carroll RS, Black PM. Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas. Neurosurgery. 2000 Nov; 47(5):1185-95. PMID: 11063113.
      View in: PubMed
    110. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):12227-32. PMID: 11035804; PMCID: PMC17323.
    111. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000 Aug; 6(8):3056-61. PMID: 10955784.
      View in: PubMed
    112. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J. 2000 May; 6 Suppl 3:S245-9. PMID: 10874494.
      View in: PubMed
    113. Huang S, Stupack D, Liu A, Cheresh D, Nemerow GR. Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of alpha(v) integrins. Oncogene. 2000 Apr 06; 19(15):1915-23. PMID: 10773881.
      View in: PubMed
    114. Wang K, Guan T, Cheresh DA, Nemerow GR. Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin beta5. J Virol. 2000 Mar; 74(6):2731-9. PMID: 10684289; PMCID: PMC111763.
    115. Bonfoco E, Chen W, Paul R, Cheresh DA, Cooper NR. beta1 integrin antagonism on adherent, differentiated human neuroblastoma cells triggers an apoptotic signaling pathway. Neuroscience. 2000; 101(4):1145-52. PMID: 11113363.
      View in: PubMed
    116. Leng J, Klemke RL, Reddy AC, Cheresh DA. Potentiation of cell migration by adhesion-dependent cooperative signals from the GTPase Rac and Raf kinase. J Biol Chem. 1999 Dec 31; 274(53):37855-61. PMID: 10608850.
      View in: PubMed
    117. Collins LR, Ricketts WA, Yeh L, Cheresh D. Bifurcation of cell migratory and proliferative signaling by the adaptor protein Shc. J Cell Biol. 1999 Dec 27; 147(7):1561-8. PMID: 10613912; PMCID: PMC2174237.
    118. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 1999 Dec; 4(6):915-24. PMID: 10635317.
      View in: PubMed
    119. Cheresh DA, Leng J, Klemke RL. Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol. 1999 Sep 06; 146(5):1107-16. PMID: 10477763; PMCID: PMC2169492.
    120. Pampori N, Hato T, Stupack DG, Aidoudi S, Cheresh DA, Nemerow GR, Shattil SJ. Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J Biol Chem. 1999 Jul 30; 274(31):21609-16. PMID: 10419468.
      View in: PubMed
    121. Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 1999 Jun 01; 59(11):2724-30. PMID: 10363998.
      View in: PubMed
    122. Stupack DG, Storgard CM, Cheresh DA. A role for angiogenesis in rheumatoid arthritis. Braz J Med Biol Res. 1999 May; 32(5):573-81. PMID: 10412569.
      View in: PubMed
    123. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999 May; 103(9):1227-30. PMID: 10225964; PMCID: PMC408360.
    124. Stupack DG, Li E, Silletti SA, Kehler JA, Geahlen RL, Hahn K, Nemerow GR, Cheresh DA. Matrix valency regulates integrin-mediated lymphoid adhesion via Syk kinase. J Cell Biol. 1999 Feb 22; 144(4):777-88. PMID: 10037798; PMCID: PMC2132930.
    125. Lode HN, Moehler T, Xiang R, Jonczyk A, Gillies SD, Cheresh DA, Reisfeld RA. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci U S A. 1999 Feb 16; 96(4):1591-6. PMID: 9990069; PMCID: PMC15528.
    126. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest. 1999 Jan; 103(1):47-54. PMID: 9884333; PMCID: PMC407856.
    127. Brooks PC, Montgomery AM, Cheresh DA. Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol. 1999; 129:257-69. PMID: 10494570.
      View in: PubMed
    128. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis. Mol Med. 1998 Dec; 4(12):741-50. PMID: 9990860; PMCID: PMC2230391.
    129. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R, Cheresh DA. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998 Nov; 4(11):2625-34. PMID: 9829725.
      View in: PubMed
    130. Nicolaou KC, Trujillo JI, Jandeleit B, Chibale K, Rosenfeld M, Diefenbach B, Cheresh DA, Goodman SL. Design, synthesis and biological evaluation of nonpeptide integrin antagonists. Bioorg Med Chem. 1998 Aug; 6(8):1185-208. PMID: 9784861.
      View in: PubMed
    131. Rader C, Cheresh DA, Barbas CF. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci U S A. 1998 Jul 21; 95(15):8910-5. PMID: 9671778; PMCID: PMC21176.
    132. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998 May; 4(5):623-6. PMID: 9585240.
      View in: PubMed
    133. Cheresh DA. Death to a blood vessel, death to a tumor. Nat Med. 1998 Apr; 4(4):395-6. PMID: 9546782.
      View in: PubMed
    134. Eliceiri BP, Klemke R, Strömblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998 Mar 09; 140(5):1255-63. PMID: 9490736; PMCID: PMC2132684.
    135. Li E, Stupack D, Klemke R, Cheresh DA, Nemerow GR. Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. J Virol. 1998 Mar; 72(3):2055-61. PMID: 9499060; PMCID: PMC109499.
    136. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol. 1998 Feb 23; 140(4):961-72. PMID: 9472046; PMCID: PMC2141747.
    137. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998 Feb 06; 92(3):391-400. PMID: 9476898.
      View in: PubMed
    138. van der Zee R, Murohara T, Passeri J, Kearney M, Cheresh DA, Isner JM. Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis. Cell Adhes Commun. 1998; 6(5):371-9. PMID: 10223353.
      View in: PubMed
    139. Felding-Habermann B, Silletti S, Mei F, Siu CH, Yip PM, Brooks PC, Cheresh DA, O'Toole TE, Ginsberg MH, Montgomery AM. A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple vascular and platelet integrins. J Cell Biol. 1997 Dec 15; 139(6):1567-81. PMID: 9396761; PMCID: PMC2132622.
    140. Boudreau N, Andrews C, Srebrow A, Ravanpay A, Cheresh DA. Induction of the angiogenic phenotype by Hox D3. J Cell Biol. 1997 Oct 06; 139(1):257-64. PMID: 9314544; PMCID: PMC2139816.
    141. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997 Apr 21; 137(2):481-92. PMID: 9128257; PMCID: PMC2139771.
    142. Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest. 1997 Mar 15; 99(6):1390-8. PMID: 9077549; PMCID: PMC507955.
    143. Strömblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol. 1996 Dec; 6(12):462-8. PMID: 15157503.
      View in: PubMed
    144. Yebra M, Parry GC, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem. 1996 Nov 15; 271(46):29393-9. PMID: 8910604.
      View in: PubMed
    145. Strömblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol. 1996 Nov; 3(11):881-5. PMID: 8939711.
      View in: PubMed
    146. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol. 1996 Oct; 8(5):724-30. PMID: 8939661.
      View in: PubMed
    147. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996 Sep 03; 93(18):9764-9. PMID: 8790405; PMCID: PMC38503.
    148. Lewis JM, Cheresh DA, Schwartz MA. Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J Cell Biol. 1996 Sep; 134(5):1323-32. PMID: 8794871; PMCID: PMC2120976.
    149. Strömblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest. 1996 Jul 15; 98(2):426-33. PMID: 8755653; PMCID: PMC507446.
    150. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA, del Zoppo GJ. Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischemia. Am J Pathol. 1996 Jul; 149(1):37-44. PMID: 8686760; PMCID: PMC1865237.
    151. Chellaiah M, Fitzgerald C, Filardo EJ, Cheresh DA, Hruska KA. Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit. Endocrinology. 1996 Jun; 137(6):2432-40. PMID: 8641196.
      View in: PubMed
    152. Filardo EJ, Deming SL, Cheresh DA. Regulation of cell migration by the integrin beta subunit ectodomain. J Cell Sci. 1996 Jun; 109 ( Pt 6):1615-22. PMID: 8799848.
      View in: PubMed
    153. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996 May 31; 85(5):683-93. PMID: 8646777.
      View in: PubMed
    154. Clark RA, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. Am J Pathol. 1996 May; 148(5):1407-21. PMID: 8623913; PMCID: PMC1861547.
    155. Montgomery AM, Becker JC, Siu CH, Lemmon VP, Cheresh DA, Pancook JD, Zhao X, Reisfeld RA. Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol. 1996 Feb; 132(3):475-85. PMID: 8636223; PMCID: PMC2120722.
    156. Wilson CB, Leopard J, Cheresh DA, Nakamura RM. Extracellular matrix and integrin composition of the normal bladder wall. World J Urol. 1996; 14 Suppl 1:S30-7. PMID: 8738408.
      View in: PubMed
    157. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol. 1996; 69-87. PMID: 8791129.
      View in: PubMed
    158. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995 Dec 01; 270(5241):1500-2. PMID: 7491498.
      View in: PubMed
    159. Varner JA, Brooks PC, Cheresh DA. REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes Commun. 1995 Nov; 3(4):367-74. PMID: 8821037.
      View in: PubMed
    160. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995 Oct; 96(4):1815-22. PMID: 7560073; PMCID: PMC185818.
    161. Wilson CB, Leopard J, Nakamura RM, Cheresh DA, Stein PC, Parsons CL. Selective type IV collagen defects in the urothelial basement membrane in interstitial cystitis. J Urol. 1995 Sep; 154(3):1222-6. PMID: 7637092.
      View in: PubMed
    162. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci. 1995 Jul; 108 ( Pt 7):2655-61. PMID: 7593306.
      View in: PubMed
    163. Yebra M, Filardo EJ, Bayna EM, Kawahara E, Becker JC, Cheresh DA. Induction of carcinoma cell migration on vitronectin by NF-kappa B-dependent gene expression. Mol Biol Cell. 1995 Jul; 6(7):841-50. PMID: 7579698; PMCID: PMC301244.
    164. Filardo EJ, Brooks PC, Deming SL, Damsky C, Cheresh DA. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol. 1995 Jul; 130(2):441-50. PMID: 7542248; PMCID: PMC2199943.
    165. Hruska KA, Rolnick F, Huskey M, Alvarez U, Cheresh D. Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology. 1995 Jul; 136(7):2984-92. PMID: 7540546.
      View in: PubMed
    166. Hruska KA, Rolnick F, Huskey M, Alvarez U, Cheresh D. Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Ann N Y Acad Sci. 1995 Apr 21; 760:151-65. PMID: 7540372.
      View in: PubMed
    167. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci. 1995 Mar; 108 ( Pt 3):947-56. PMID: 7542670.
      View in: PubMed
    168. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995 Feb; 95(2):713-24. PMID: 7532190; PMCID: PMC295539.
    169. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30; 79(7):1157-64. PMID: 7528107.
      View in: PubMed
    170. Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol. 1994 Nov; 127(3):859-66. PMID: 7525598; PMCID: PMC2120222.
    171. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol. 1994 Oct; 127(1):257-64. PMID: 7523420; PMCID: PMC2120185.
    172. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A. 1994 Sep 13; 91(19):8856-60. PMID: 7522323; PMCID: PMC44705.
    173. Delannet M, Martin F, Bossy B, Cheresh DA, Reichardt LF, Duband JL. Specific roles of the alpha V beta 1, alpha V beta 3 and alpha V beta 5 integrins in avian neural crest cell adhesion and migration on vitronectin. Development. 1994 Sep; 120(9):2687-702. PMID: 7525179; PMCID: PMC2710119.
    174. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994 Apr 22; 264(5158):569-71. PMID: 7512751.
      View in: PubMed
    175. Filardo EJ, Cheresh DA. A beta turn in the cytoplasmic tail of the integrin alpha v subunit influences conformation and ligand binding of alpha v beta 3. J Biol Chem. 1994 Feb 11; 269(6):4641-7. PMID: 7508446.
      View in: PubMed
    176. Nemerow GR, Cheresh DA, Wickham TJ. Adenovirus entry into host cells: a role for alpha(v) integrins. Trends Cell Biol. 1994 Feb; 4(2):52-5. PMID: 14731867.
      View in: PubMed
    177. Filardo EJ, Cheresh DA. A structural basis for bidirectional integrin signalling. Princess Takamatsu Symp. 1994; 24:106-17. PMID: 8983068.
      View in: PubMed
    178. Zeballos RS, Fox RI, Cheresh DA, McPherson RA. Anti-glycosphingolipid autoantibodies in rheumatologic disorders. J Clin Lab Anal. 1994; 8(6):378-84. PMID: 7869176.
      View in: PubMed
    179. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993 Oct; 5(5):864-8. PMID: 7694604.
      View in: PubMed
    180. Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL, Cheresh DA. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993 May 05; 268(13):9901-7. PMID: 8486670.
      View in: PubMed
    181. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993 Apr 23; 73(2):309-19. PMID: 8477447.
      View in: PubMed
    182. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol. 1993 Apr; 121(1):163-70. PMID: 7681432; PMCID: PMC2119781.
    183. Nip J, Shibata H, Loskutoff DJ, Cheresh DA, Brodt P. Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J Clin Invest. 1992 Oct; 90(4):1406-13. PMID: 1383272; PMCID: PMC443186.
    184. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol. 1992 Jun; 117(5):1101-7. PMID: 1374415; PMCID: PMC2289489.
    185. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest. 1992 Jun; 89(6):2018-22. PMID: 1376331; PMCID: PMC295910.
    186. Cheresh DA. Structural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med. 1992 Jun; 12(2):217-36. PMID: 1611819.
      View in: PubMed
    187. Felding-Habermann B, Ruggeri ZM, Cheresh DA. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem. 1992 Mar 15; 267(8):5070-7. PMID: 1531979.
      View in: PubMed
    188. Sanders LC, Felding-Habermann B, Mueller BM, Cheresh DA. Role of alpha V integrins and vitronectin in human melanoma cell growth. Cold Spring Harb Symp Quant Biol. 1992; 57:233-40. PMID: 1285050.
      View in: PubMed
    189. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 1991 Dec; 88(6):1924-32. PMID: 1721625; PMCID: PMC295768.
    190. Cheresh DA. Integrins in thrombosis, wound healing and cancer. Biochem Soc Trans. 1991 Nov; 19(4):835-8. PMID: 1794568.
      View in: PubMed
    191. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, Zambonin-Zallone A, Ross FP, Teitelbaum SL, Cheresh D. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem. 1991 Oct 25; 266(30):20369-74. PMID: 1939092.
      View in: PubMed
    192. Orlando RA, Cheresh DA. Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin alpha v beta 3 and its ligand. J Biol Chem. 1991 Oct 15; 266(29):19543-50. PMID: 1717468.
      View in: PubMed
    193. Smith JW, Cheresh DA. Labeling of integrin alpha v beta 3 with 58Co(III). Evidence of metal ion coordination sphere involvement in ligand binding. J Biol Chem. 1991 Jun 25; 266(18):11429-32. PMID: 1711032.
      View in: PubMed
    194. Cheresh DA. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev. 1991 May; 10(1):3-10. PMID: 1717171.
      View in: PubMed
    195. Wayner EA, Orlando RA, Cheresh DA. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol. 1991 May; 113(4):919-29. PMID: 1709170; PMCID: PMC2288998.
    196. Kieffer N, Fitzgerald LA, Wolf D, Cheresh DA, Phillips DR. Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol. 1991 Apr; 113(2):451-61. PMID: 1707057; PMCID: PMC2288943.
    197. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 1991 Jan 01; 77(1):75-83. PMID: 1702031.
      View in: PubMed
    198. Charo IF, Nannizzi L, Smith JW, Cheresh DA. The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol. 1990 Dec; 111(6 Pt 1):2795-800. PMID: 1703545; PMCID: PMC2116382.
    199. McLean JW, Vestal DJ, Cheresh DA, Bodary SC. cDNA sequence of the human integrin beta 5 subunit. J Biol Chem. 1990 Oct 05; 265(28):17126-31. PMID: 2211615.
      View in: PubMed
    200. Harel W, Shau H, Hadley CG, Morgan AC, Reisfeld RA, Cheresh DA, Mitchell MS. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res. 1990 Oct 01; 50(19):6311-5. PMID: 2400994.
      View in: PubMed
    201. Ylänne J, Cheresh DA, Virtanen I. Localization of beta 1, beta 3, alpha 5, alpha v, and alpha IIb subunits of the integrin family in spreading human erythroleukemia cells. Blood. 1990 Aug 01; 76(3):570-7. PMID: 1696147.
      View in: PubMed
    202. Smith JW, Ruggeri ZM, Kunicki TJ, Cheresh DA. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem. 1990 Jul 25; 265(21):12267-71. PMID: 2373693.
      View in: PubMed
    203. Smith JW, Vestal DJ, Irwin SV, Burke TA, Cheresh DA. Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. J Biol Chem. 1990 Jul 05; 265(19):11008-13. PMID: 1694173.
      View in: PubMed
    204. Rudolph R, Cheresh D. Cell adhesion mechanisms and their potential impact on wound healing and tumor control. Clin Plast Surg. 1990 Jul; 17(3):457-62. PMID: 1696193.
      View in: PubMed
    205. Smith JW, Cheresh DA. Getting unglued about integrins. The Molecular Basis of Cellular Adhesion: A UCLA symposium, sponsored by Genentech and Glaxo Steamboat Springs, CO, USA, January 20-26, 1990. New Biol. 1990 Jun; 2(6):518-22. PMID: 1982422.
      View in: PubMed
    206. Smith JW, Cheresh DA. Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem. 1990 Feb 05; 265(4):2168-72. PMID: 1688848.
      View in: PubMed
    207. Krissansen GW, Elliott MJ, Lucas CM, Stomski FC, Berndt MC, Cheresh DA, Lopez AF, Burns GF. Identification of a novel integrin beta subunit expressed on cultured monocytes (macrophages). Evidence that one alpha subunit can associate with multiple beta subunits. J Biol Chem. 1990 Jan 15; 265(2):823-30. PMID: 1688554.
      View in: PubMed
    208. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell. 1989 Sep 08; 58(5):945-53. PMID: 2673537.
      View in: PubMed
    209. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989 Jun 01; 49(11):2857-61. PMID: 2720646.
      View in: PubMed
    210. Cheresh DA, Smith JW, Cooper HM, Quaranta V. A novel vitronectin receptor integrin (alpha v beta x) is responsible for distinct adhesive properties of carcinoma cells. Cell. 1989 Apr 07; 57(1):59-69. PMID: 2467745.
      View in: PubMed
    211. Lam SC, Plow EF, D'Souza SE, Cheresh DA, Frelinger AL, Ginsberg MH. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem. 1989 Mar 05; 264(7):3742-9. PMID: 2465293.
      View in: PubMed
    212. Cheresh DA. Human melanoma cell attachment involves an Arg-Gly-Asp-directed adhesion receptor and the disialoganglioside GD2. Prog Clin Biol Res. 1989; 288:3-24. PMID: 2470110.
      View in: PubMed
    213. Smith JW, Cheresh DA. The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. J Biol Chem. 1988 Dec 15; 263(35):18726-31. PMID: 2461930.
      View in: PubMed
    214. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987 Dec 25; 262(36):17703-11. PMID: 2447074.
      View in: PubMed
    215. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A. 1987 Sep; 84(18):6471-5. PMID: 2442758; PMCID: PMC299099.
    216. Cheresh DA, Pytela R, Pierschbacher MD, Klier FG, Ruoslahti E, Reisfeld RA. An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol. 1987 Sep; 105(3):1163-73. PMID: 2443507; PMCID: PMC2114807.
    217. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol. 1987 May 15; 138(10):3566-72. PMID: 2437198.
      View in: PubMed
    218. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987 Feb 15; 47(4):1098-104. PMID: 3100030.
      View in: PubMed
    219. Reisfeld RA, Cheresh DA. Human tumor antigens. Adv Immunol. 1987; 40:323-77. PMID: 3591561.
      View in: PubMed
    220. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res. 1986 Oct; 46(10):5112-8. PMID: 3019521.
      View in: PubMed
    221. Cheresh DA, Klier FG. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol. 1986 May; 102(5):1887-97. PMID: 3084502; PMCID: PMC2114226.
    222. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986 Mar; 102(3):688-96. PMID: 3005335; PMCID: PMC2114134.
    223. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci U S A. 1985 Aug; 82(15):5155-9. PMID: 3860849; PMCID: PMC390518.
    224. Sportsman JR, Park MM, Cheresh DA, Fukuda M, Elder JH, Fox RI. Characterization of a membrane surface glycoprotein associated with T-cell activation. J Immunol. 1985 Jul; 135(1):158-64. PMID: 2987344.
      View in: PubMed
    225. Reisfeld RA, Cheresh DA. Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy. Cancer Surv. 1985; 4(1):271-90. PMID: 3916082.
      View in: PubMed
    226. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984 Dec; 44(12 Pt 1):5914-20. PMID: 6498849.
      View in: PubMed
    227. Cheresh DA, Harper JR, Schulz G, Reisfeld RA. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A. 1984 Sep; 81(18):5767-71. PMID: 6385004; PMCID: PMC391792.
    228. Cheresh DA, Reisfeld RA, Varki AP. O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science. 1984 Aug 24; 225(4664):844-6. PMID: 6206564.
      View in: PubMed
    229. Cheresh DA, Varki AP, Varki NM, Stallcup WB, Levine J, Reisfeld RA. A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem. 1984 Jun 25; 259(12):7453-9. PMID: 6203895.
      View in: PubMed